Journal of Surgery & Clinical Practice

Extended Abstract

Innovations in an orphan disease: Male breast cancer

Atahan Acar

Izmir Katip Celebi University, Turkey

E-mail: birelinnesivarikielinsesivar@gmail.com

Abstract

Male carcinoma (MBC) could be a very rare disease with a rising incidence in recent years. Although there are many similarities with carcinoma in women, some obvious differences have been shown. This speaking is aimed to draw attention with the present information of this rare entity. MBC could be a rare disease, accounting for less than 1% of all malignancies in men and for less than 1% of all incidents of breast carcinoma. Factors which are related to an increased risk are aging, case history of carcinoma, inherited gene mutations, Klinefelter syndrome, radiation exposure, alcoholic beverages intake, disease, estrogen treatment, obesity, physical inactivity, testicular conditions, and certain occupations. Although these factors may increase a man's risks of developing carcinoma, the reason for most BMC is unknown. Most information on causes, prevention and treatment of carcinoma from clinical trials and research throughout the globe were worn out women. Recent studies concentrate on genetic testing totally on BRCA1 and BRCA2 mutations and also other genes that contribute to carcinoma risk also are being identified. Findings reveal that the results of genetic variations on the danger of carcinoma in men and ladies are different. New laboratory test as circulating tumour cells and also the effect of environment have also received more attention in recent years. More convenient ways of therapy and innovations in chemotherapy strategies by PARP (Poly ADP Ribose Polymerase) inhibitors and targeted therapies are quite popular. 2,470 newly diagnosed cases of invasive MBC were estimated by The American Cancer Society at the start of 2017 and also it had been estimated that 460 of them would die. of these improvements of this orphan disease is also will ready to save patients children from being orphans.

Atahan has completed his Graduation from grad School of Ankara University. He has completed General Surgery Residency at Ministry of Health, Ankara Numune Education and Research Hospital, Ankara, Turkey. He has served as a General Surgeon at Cankiri Ilgaz State Hospital and as a Surgeon and Head Physician at Burhaniye and Edremit State Hospitals at Balikesir Province. He's working as a Specialist at the primary Department of Surgery, Izmir Katip Celebi University Ataturk Education and Research Hospital. He has received certificate of Fellowship in minimal access surgery at World Laparoscopy Hospital at Gurgaon, Haryana, India.

Purpose of review: Male carcinoma (MaBC) could be a rare disease, and a few challenges exist in its management because current treatment recommendations are extrapolated from trials that mostly excluded men. This review will revise all available data that might improve the treatment of MaBC, with a special specialise in adjuvant systemic treatments.

Recent findings: so far, men with hormone receptor-positive carcinoma, who are candidates for adjuvant endocrine therapy, should be offered tamoxifen (TAM) for five years. Additional five years are possible, per tolerance and recurrence risk. If TAM is contraindicated, a gonadotropin-releasing hormone (GnRH) agonist or antagonist and aromatase inhibitor should be proposed. Chemotherapy and targeted therapy within the other carcinoma subtypes should be used with the identical indications offered to women with carcinoma. All men with carcinoma should be offered counsel and germline genetic testing of cancer predisposition genes

For decades, men with carcinoma are treated sub optimally and denied the participation in clinical trials. Recently, many clinical trials started enrolling both genders, as strongly endorsed by the Food and Drug Administration. Hopefully, this turnaround will help subdue the disparities within the quality of care. To develop recommendations concerning the management of male carcinoma.

ASCO convened an Expert Panel to develop recommendations supported a scientific review and a proper consensus process. Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations.

Recommendations: Many of the management approaches used for men with carcinoma are like those used for ladies. Men with hormone receptor-positive carcinoma who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of 5 years; those with a contraindication to tamoxifen are also offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence is also offered a further five years of therapy. Men with early-stage disease mustn't be treated with bone-modifying agents to forestall recurrence, but could still receive these agents to stop or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy could also be wont to treat advanced or metastatic cancer using the identical indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of carcinoma treated with lumpectomy irrespective of genetic predisposition; contralateral annual mammogram could also be offered to men with a history of carcinoma and a genetic predisposing mutation. Breast resonance

Journal of Surgery & Clinical Practice

Extended Abstract

imaging isn't recommended routinely. Guidance and germline genetic testing of cancer predisposition genes should be offered to any or all men with carcinoma.

Male carcinoma (MBC) could be a rare tumor, accounting for less than 1% of all breast cancers. In MBC, genetic predisposition plays a vital role; however, only some studies have investigated full the role of genes aside from BRCA1 and BRCA2. We performed a Next-Generation Sequencing (NGS) analysis with a panel of 94 cancer predisposition genes on germline DNA from an Italian case series of 70 patients with MBC. Moreover, we looked for large deletions/duplications of BRCA1/2 genes through the Multiplex Ligation-dependent Probe Amplification (MLPA) technique. Through the mix of NGS and MLPA, we identified three pathogenic variants within the BRCA1 gene and 6 within the BRCA2 gene. Besides these alterations, we found six additional pathogenic/likely-pathogenic variants in PALB2, CHEK2, ATM, RAD51C, BAP1 and EGFR genes. From our study, BRCA1 and BRCA2 emerge because the main genes related to MBC risk, but also other genes seem to be related to the disease. Indeed, a number of these genes have already been implicated in female carcinoma predisposition, but others are known to be involved in other forms of cancer. Consequently, our results suggest that novel genes may well be involved in MBC susceptibility, shedding new light on their role in cancer development.